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Learning objectives
By the end of this module the reader should be able to:
• describe the biomedical concepts underlying intra-
prostatic injections for benign prostatic hyperplasia 
(BPH)
• explain how the different types of intra-prostatic injec-
tion are administered
• appraise the existing literature relating to intra-prostat-
ic injections.
Introduction
Lower urinary tract symptoms (LUTS) secondary to blad-
der outlet obstruction (BOO) from benign prostatic hyper-
plasia (BPH) can have a significant impact on the quality of 
life of older men [1]. Epidemiological data have shown that 
more than 50% of men aged 70 and above report mod-
erate to severe LUTS [2, 3]. The current treatment options 
for LUTS/BPH broadly consist of a conservative “wait and 
see” approach, pharmacotherapy and a variety of surgical 
options [4-6].
LUTS secondary to BPH have a multifactorial pathogene-
sis, resulting in a spectrum of clinical presentations. Broad-
ly speaking α1-adrenoceptor antagonists, 5α-reductase in-
hibitors, muscarinic receptor antagonists, β3-adrenoceptor 
agonists and phosphodiesterase type 5 inhibitors are all 
recognised pharmacotherapeutic agents for LUTS/BPH. 
The above medication groups may be used as monother-
apy or in combination [1]. Problems with existing medical 
treatments include lack of compliance and adverse effects 
such as postural hypotension, dizziness and impaired sex-
ual function. Pharmacotherapy fails to resolve symptoms 
sufficiently in 30% of men, for whom the only remaining 
option is surgery [7, 8].
Transurethral resection of the prostate (TURP) is consid-
ered to be the gold standard minimally invasive treatment 
for BPH. However, while safe and effective, it has a periop-
erative morbidity rate of up to 20% and is associated with 
longer-term complications such as erectile dysfunction, 
urinary incontinence and urethral stricture [1]. The chal-
lenge in the 21st century is to develop alternative treat-
ments that replicate the effectiveness of TURP without the 
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unwanted side effect profile.
Ethanol ablation
Ethanol ablation involves the use of a flexible injection 
needle to inject dehydrated ethanol into the prostate for 
the purposes of chemoablation of tissue. The procedure 
is often performed under cystoscopic guidance and it may 
be injected via a transurethral, transperineal, or transrectal 
approach. Inflammation and coagulative necrosis results 
in cavity formation and destruction of afferent nerves [9, 
10]. The procedure is typically performed under sedation 
or spinal anaesthesia. Ethanol ablation is the oldest and 
most extensively studied injectable agent used for treating 
BPH.
The first clinical study into ethanol ablation was published 
in 1999 [11]. Statistically significant improvements in IPSS, 
Qmax and post-void residual were demonstrated at three 
months follow-up, with a sample size of 10 men. A phase 
I/II multi-centre randomised trial with 79 participants dem-
onstrated statistically significant improvement after etha-
nol ablation across a range of clinical outcomes; at six 
months follow-up mean prostate volume had decreased 
from 46.1g to 39.8g with a 10.6 point improvement in IPSS 
[12]. However, the favourable initial results were seldom 
maintained, and re-treatment with another modality was 
required in at least 40% of patients [13]. 
One concern regarding prostatic ethanol ablation is the 
difficulty in controlling distribution and the potential risk of 
bladder necrosis due to inadvertent injection [14, 15]. Use of 
anhydrous ethanol in a gel formulation has been described 
as a potential solution to this problem. A case series with 
65 patients reported statistically significant improvements 
in IPSS and flow rate [16]. 
Another study followed up 56 men for 54 months, assess-
ing outcomes including International Prostate System 
Score (IPSS), prostate volume (measured via TRUS), 
prostate-specific antigen (PSA), Qmax and post void re-
sidual. Seventy-three percent of patients had a satisfactory 
response, while 23% required another form of treatment. 
However, there was a relatively high loss to follow-up and 
a lack of data regarding sexual function and continence in 
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arm seemed impressive, the mean decrease corrected for 
control was only 3.3 points at three months, dropping to a 
non-statistically significant 2.8 points at 12-month follow-
up. Mean change in Qmax in the treatment arm was not 
statistically significant at 12 months compared to baseline 
and there were no clinically relevant beneficial effects on 
post void residual volume or prostatic volume. Adverse 
events were mild to moderate in severity, resolving within 
a median duration of less than 48 hours.
The results from a phase III multi-centre, randomised, 
double-blinded, placebo controlled trial conducted by the 
manufacturer were published in 2015 [22]. The premise of 
the study was to assess the safety and efficacy of a single 
intra-prostatic injection of PRX302 for BPH. The data from 
479 participants with 12 months follow-up were analysed. 
While there was a statistically significant improvement in 
IPSS in the PRX302 group compared to the control group, 
there was no statistically significant improvement in Qmax. 
Adverse effects included dysuria, haematuria, frequency 
and perineal pain and were similar to the control group. 
PRX-302-related adverse events included moderate in-
stances of acute non-infectious prostatitis [22].
Interestingly, the role of PRX302 in treating localised low- 
to intermediate-risk prostate cancer is currently being stud-
ied in a stage 2b multi-centre trial conducted by the manu-
facturer. The study aims to evaluate the safety, tolerability 
and efficacy of PRX302 intra-prostatic focal injection and 
to determine an effective and tolerable dose. Efficacy will 
be assessed by prostatic biopsy and multi-parametric MRI 
scan at 24 weeks post administration. The estimated date 
of study completion is December 2018 [23].
NX-1207 (Fexapotide Triflutate)
Fexapotide Triflutate (NX-1207) is a protein that reduces 
prostate volume by inducing selective apoptosis [24, 25]. A 
single administration of the drug is injected into the transi-
tion zone of the prostate leading to non-regressive pros-
tate shrinkage and symptomatic relief [10]. The detailed 
mechanism of action has not been published by the manu-
facturer. Two phase II multicentre studies with 175 and 85 
men have demonstrated statistically significant improve-
ments in American Urological Association Symptom Index 
(AUASI) scores and prostate volume in men with severe 
LUTS and a prostate volume between 30mL and 70mL. 
One of these studies was a multicentre, randomised, non-
inferiority study with two doses of NX-1207 (0.125mg and 
2.5mg) compared to finasteride [24]. The dose of NX-1207 
was double-blinded and the primary outcome was an im-
provement in AUA symptom score at 90 and 180 days 
compared to finasteride. Inclusion criteria included a Qmax 
of less 15mL per second and a prostate volume of >30mL 
and ≤70mL. Mean improvement in AUA symptom score at 
90 days was 9.71 points for the 2.5mg NX-1207 cohort, 
4.29 for the 0.125mg NX-1207 cohort, and 4.13 for the 
this study [17].
There have been a number of reported complications with 
ethanol ablation including haematuria, dysuria, urinary 
retention, urinary tract infection and urinary incontinence. 
There have been reports of erectile dysfunction and ejacu-
latory problems despite taking care to avoid the bladder 
neck. This is thought to be secondary to dissipation of the 
injected ethanol. Major complications such as widespread 
bladder necrosis leading to cystectomy has led to ethanol 
ablation being abandoned as a viable therapeutic option 
[6, 10, 14].
PRX302/Topsalysin
PRX302 (also known as Topsalysin) is a novel targeted 
therapy for BPH that causes a reduction in transition zone 
volume via cellular involution. PRX302 can be adminis-
tered under local anaesthesia either via a transperineal 
or transrectal route and under transrectal ultrasound guid-
ance [18, 19]. PRX302 is a genetically modified form of pro-
aerolysin, a highly toxic bacterial pore-forming pro-toxin 
produced by the aquatic pathogen Aeromonas hydrophila 
[20]. Cleavage by furin proteases produces an active me-
tabolite, aerolysin, which forms highly stable pores in cell 
plasma membranes, causing apoptosis. With PRX302, the 
native furin protease activation site is replaced with a PSA-
recognised sequence, which is activated by PSA through 
a process known as proteolyic processing.  The activity of 
PRX302 is confined exclusively to the prostate, which has 
an abundance of active PSA [1]. Based on the above mod-
el, injection of PRX302 into the transition zone may allevi-
ate LUTS as a direct result of prostatic volume reduction.
A phase II trial, published in 2011, evaluated different vol-
umes of PRX302 at a fixed concentration, adjusted for pros-
tate size in 18 participants [18]. A ≥ 30% reduction in IPSS 
was maintained at 12 months in 63% of participants. A sta-
tistically significant improvement in Qmax was observed in 
61% of participants at 12-month follow-up. Administration 
of PRX302 led to a ≥ 20% reduction in prostatic volume in 
63% of study participants at 12-month follow-up. Compli-
cations in both trials included dysuria, perineal pain/bruis-
ing, haematuria and storage lower urinary tract symptoms. 
All complications were mild to moderate, resolving within 
72 hours [18].
The results of a multicentre, prospective, randomised, 
double-blinded, placebo-controlled phase IIb clinical trial 
of PRX302 were published in 2013 [21]. Inclusion criteria for 
the study included severe IPSS and a prostate volume of 
30–100mL. A total of 92 patients were eligible and randomly 
assigned to receive a fixed concentration of PRX302 – ad-
justed to be 20% of the prostatic volume – or the placebo 
control. End points included change in IPSS score, Qmax, 
post void residual and prostatic volume. While a mean 
reduction in IPSS of nearly nine points for the treatment 
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crosis at injection sites and a more widespread apoptotic 
reaction [10, 30-33].
It has been reported that intra-prostatic botulinum toxin 
downregulates the expression of a1-adrenergic receptors, 
which may result in smooth muscle relaxation [30]. Intra-
prostatic botulinum toxin may be administered via a trans-
perineal, transurethral or transrectal approach. While simi-
lar results have been reported following injection of 100 
and 200 international units (IU) of intra-prostatic botulinum 
toxin, the optimal dose is yet to be determined. 100IU has 
been described as preferable due to a similar efficacy to 
higher doses, with reduced costs and adverse effects [34, 
35].
A recent placebo-controlled phase II study randomly as-
signed 380 men to receive either 100IU, 200IU, 300IU or 
placebo (0.9% saline). While there were improvements in 
IPSS, maximum flow (Qmax) and quality of life 72 weeks 
after administration of intra-prostatic botulinum toxin, there 
was a significant placebo effect with no significant differ-
ence demonstrated between treatment and control arms 
[36]. A prospective single-armed cohort study evaluated 
patient-reported and objective outcomes following admin-
istration of intra-prostatic botulinum toxin in 64 men with 
symptomatic BPH, refractory to medical treatment. 200IU 
were administered into the transition zone via a transperi-
neal approach. The study demonstrated a statistically sig-
nificant positive correlation between patient satisfaction 
and both baseline IPSS and reduction rate in IPSS [37].
There have been minimal reported side effects of intra-
prostatic botulinum toxin and it is well tolerated. However, 
retreatment rates are as high as 29% [38]. Reported side 
effects of the procedure include urinary tract infection and/
or urosepsis, acute urinary retention and haematuria [35]. 
There have been no reported effects on sexual function [10, 
39, 40]. Limitations of the existing research into intra-prostatic 
botulinum toxin include a significant placebo effect, limited 
follow-up, lack of randomisation and/or systematic evalua-
tion of appropriate dose regimens [41].
Current international guideline recommenda-
tions
The AUA and NICE do not currently consider injectable 
agents as potential treatment options for BPH [5, 42]. NICE 
actively discourages the use of ethanol ablation. The EAU 
guidelines state that ethanol ablation and intra-prostatic 
botulinum toxin are experimental treatment options for 
BPH and should only be considered within the context of 
clinical trials [41]. No additional injectable agents have yet 
been considered by the AUA, EAU or NICE, and no inject-
able agents are currently licensed for use within the UK, 
outside of the context of a clinical trial.
finasteride cohort. There was a statistically significant im-
provement in AUA symptom score in the 2.5mg NX-1207 
cohort compared to the 0.125mg and finasteride cohorts. 
More than 50% of participants in all NX-1207 phase I and 
II trials have not required any further surgical intervention 
for BPH at five years follow up [6, 24, 26]. The side effect pro-
file of NX-1207 in trials to date is minimal with no adverse 
effects on sexual function or urinary incontinence reported 
[10]. While mild haematuria, dysuria and urinary tract infec-
tions have been reported, there has been no significant 
difference compared to placebo/equivalent transrectal pro-
cedures [6]. 
The results of two phase III trials (n = 978) were published 
by the manufacturer in July 2015. Primary endpoint was 
reached with a statistically significant benefit demon-
strated compared to placebo (p <0.02) at a median of 42 
months (3.5 years) follow-up. There was no evidence of 
drug-related short-term or long-term toxicity. There was 
a median improvement in AUA BPH symptoms score of 
5.3 points after a median of 3.5 years follow-up. Patients 
experienced a statistically significant reduction in BPH sur-
gery within 24 months of treatment compared to placebo; 
overall incidence of BPH surgery was low at 1.7% over a 
two-year period [27]. Following this, the manufacturer filed 
for approval to market fexapotide triflutate in five European 
countries including the UK, Germany and France in May 
2015 [28]. 
Updated data from two phase III trials were combined and 
published in January 2018 [29]. The first trial enrolled 995 
patients in two identical double-blind placebo-controlled 
prospective parallel group studies. The second pair of 
studies enrolled 344 patients in an open-label crossover 
re-injection of fexapotide at ≥ 1 year. Mean follow-up was 
43 months. There was a mean improvement in IPSS of 
5.7 points after a single injection of fexapotide, with a sta-
tistically significant difference compared to placebo from 
two years onwards. There were no significant safety dif-
ferences compared to placebo. There was a statistically 
significant reduction of AUR episodes (1.08%) and pros-
tate cancer (1.1%) in fexapotide treated patients. Need 
for additional BPH intervention was reduced in the fexa-
potide versus oral medication group (8.08% vs. 27.85% at 
three years, p < 0.0001). Incidence of intervention or AUR 
in placebo cross-over group with fexapotide versus pla-
cebo cross-over group with oral medications was reduced 
(6.07% vs. 33.3% at three years, p < 0.0001) [29].
Botulinum toxin
Botulinum toxin is produced by the bacterium Clostridium 
botulinum. There are seven subtypes of toxin, of which 
sub-type A is the most widely studied and utilised. The 
mechanism of action of intra-prostatic botulinum toxin is 
poorly understood. Theories include localised gland ne-
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Conclusion
The potential advantages of an effective intra-prostatic in-
jection are clear [43]. The ideal injectable agent should be 
relatively straightforward to administer, with minimal side 
effects and be effective and durable. Ethanol is the most 
studied injectable agent, first described 18 years ago. Early 
data were promising, but treatment durability is poor, with 
a relatively high re-treatment rate. This combined with the 
serious complication of bladder necrosis has led to etha-
nol ablation falling out of favour. Initial experimental data 
for PRX302 were also promising but the outcomes of sub-
sequent clinical trials have been more disappointing with 
the phase III trial demonstrating a statistically significant 
difference in IPSS but not in Qmax [22]. Data for NX-1207 
and intra-prostatic botulinum toxin have also been conflict-
ing. At present there is no solid evidence to support the 
potential role for injectable agents in the BPH treatment 
armamentarium, which is reflected by the lack of guideline 
recommendations.
Key learning points
• Intra-prostatic injections have been developed to 
‘bridge the gap’ between existing medical and surgical 
treatments for BPH.
• Further research is needed to demonstrate clinical ef-
ficacy.
• Potential advantages include ease of administration 
and a relatively low side effect profile.
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